| Literature DB >> 35820671 |
Sollan Kang1, Ihn Sook Jeong2.
Abstract
OBJECTIVES: This study aimed to identify the epidemiological characteristics of patients with carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii (CRE/ CRAB) isolates in a tertiary referral hospital in Korea.Entities:
Keywords: Acinetobacter baumannii; Carbapenem-resistant Enterobacteriaceae; Drug resistance, multiple
Year: 2022 PMID: 35820671 PMCID: PMC9263334 DOI: 10.24171/j.phrp.2022.0097
Source DB: PubMed Journal: Osong Public Health Res Perspect ISSN: 2210-9099
Distribution of CRE and CRAB isolates (n=528)
| Type | CRE ( | CRAB ( | Total | ||
|---|---|---|---|---|---|
| At the time of hospitalization | After hospitalization | At the time of hospitalization | After hospitalization | ||
| HA | 36 (6.8) | 116 (22.0) | 43 (8.1) | 302 (57.2) | 497 (94.1) |
| CA | 19 (3.6) | 0 (0) | 12 (2.3) | 0 (0) | 31 (5.9) |
| Total | 55 (10.4) | 116 (22.0) | 55 (10.4) | 302 (57.2) | 528 (100.0) |
Data are presented as n (%).
CRE, carbapenem-resistant Enterobacteriacae; CRAB, carbapenem-resistant Acinetobacter baumannii; HA, healthcare-acquired; CA, community-acquired.
Comparison of general characteristics, MDRO-related characteristics, and clinical outcome between patients with CRE and those with CRAB
| Variable | Category | Total ( | CRE ( | CRAB ( |
|
|---|---|---|---|---|---|
| Sex | Male | 335 (63.4) | 107 (62.6) | 228 (63.9) | 0.773 |
| Female | 193 (36.6) | 64 (37.4) | 129 (36.1) | ||
| Age (y) | 67.7±14.0 | 68.7±13.7 | 67.2±14.1 | 0.251 | |
| History of hospitalization within 6 months | No | 147 (27.8) | 33 (19.3) | 114 (30.9) | 0.006 |
| ACH | 301 (57.0) | 113 (66.1) | 188 (52.7) | ||
| LTCF | 80 (15.2) | 25 (14.6) | 55 (15.4) | ||
| Route of hospitalization | ACH, transfer | 184 (34.8) | 64 (37.4) | 12 0(33.6) | 0.680 |
| LTCF, transfer | 76 (14.4) | 23 (13.5) | 53 (14.8) | ||
| Community | 268 (50.8) | 84 (49.1) | 184 (51.5) | ||
| Comorbidities[ | Hypertension | 264 (50.0) | 100 (58.5) | 164 (45.9) | 0.007 |
| Diabetes mellitus | 186 (35.2) | 70 (40.9) | 116 (32.5) | 0.057 | |
| CVD | 158 (29.9) | 48 (28.1) | 110 (30.8) | 0.520 | |
| Cancer | 140 (26.5) | 49 (28.7) | 91 (25.5) | 0.441 | |
| CKD | 64 (12.1) | 24 (14.0) | 40 (11.2) | 0.351 | |
| Liver disease | 52 (9.8) | 23 (13.5) | 29 (8.1) | 0.055 | |
| CRD | 49 (9.3) | 15 (8.8) | 34 (9.5) | 0.781 | |
| Charlson comorbidity index score | 4.6±2.3 | 4.6±2.3 | 4.3±2.4 | 0.281 | |
| Treatment in ICU | No | 190 (36.0) | 79 (46.2) | 111 (31.1) | 0.001 |
| Yes | 338 (64.0) | 92 (53.8) | 246 (68.9) | ||
| MDRO history[ | VRE | 116 (22.0) | 48 (28.1) | 67 (19.0) | 0.019 |
| MRSA | 55 (10.4) | 20 (11.7) | 35 (9.8) | 0.505 | |
| ESBL | 88 (16.7) | 46 (26.9) | 42 (11.8) | <0.001 | |
| MRPA | 11 (2.1) | 3 (1.8) | 8 (2.2) | 1.000[ | |
| Specimen source of CRE/CRAB | Respiratory | 317 (60.0) | 15 (8.8) | 302 (84.6) | <0.001 |
| Rectal swab | 126 (23.9) | 125 (73.1) | 1 (0.3) | ||
| Urine | 33 (6.3) | 15 (8.8) | 18 (5.0) | ||
| Blood | 18 (3.4) | 2 (1.2) | 16 (4.5) | ||
| Others | 34 (6.4) | 14 (8.2) | 20 (5.6) | ||
| Strain of CRE/CRAB[ |
| 357 (67.6) | 0 (0) | 357 (100.0) | <0.001 |
| 126 (23.9) | 126 (100.0) | 0 (0) | <0.001 | ||
|
| 36 (6.8) | 36 (21.1) | 0 (0) | <0.001 | |
| 11 (2.1) | 11 (6.4) | 0 (0) | <0.001[ | ||
| Others | 3 (0.6) | 3 (1.8) | 0 (0) | <0.001[ | |
| Status at discharge | Alive | 356 (67.4) | 119 (69.6) | 237 (66.4) | 0.462 |
| Dead | 172 (32.6) | 52 (30.4) | 120 (33.6) | ||
Data are presented as n (%) or mean±standard deviation.
MDRO, multidrug-resistant organism; CRE, carbapenem-resistant Enterobacteriaceae; CRAB, carbapenem-resistant Acinetobacter baumannii; ACH, acute care hospital; LTCF, long-term care facilities; CVD, cardiovascular disease; CKD, chronic kidney disease; CRD, chronic respiratory disease; ICU, intensive care unit; VRE, vancomycin-resistant Enterococcus; MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended-spectrum β-lactamase; MRPA, multidrug-resistant Pseudomonas aeruginosa.
Multiple responses,
Fisher exact test.
Factors associated with CRAB isolation (n=418)
| Variable | OR (95% CI) |
| |
|---|---|---|---|
| Hypertension[ | 0.56 (0.35−0.89) | 0.014 | |
| Treatment in ICU[ | 0.34 (0.16−0.72) | 0.005 | |
| History of vancomycin-resistant | 0.49 (0.29−0.83) | 0.008 | |
| History of extended-spectrum β-lactamase[ | 0.48 (0.26−0.87) | 0.017 | |
| Use of mechanical ventilator[ | 3.52 (1.96−6.33) | <0.001 | |
| Use of total parenteral nutrition[ | 3.64 (1.87−7.08) | <0.001 |
CRAB, carbapenem-resistant Acinetobacter baumannii; OR, odds ratio; CI, confidence interval; ICU, intensive care unit.
Reference group=No (carbapenem-resistant Enterobacteriaceae/CRAB-isolated patients without the corresponding condition).
Comparison of treatment-related characteristics between patients with CRE and those with CRAB
| Variable | Category | Total ( | CRE ( | CRAB ( |
|
|---|---|---|---|---|---|
| Invasive procedures | Surgery | 215 (51.4) | 63 (54.3) | 152 (50.3) | 0.466 |
| Bronchoscopy | 94 (22.5) | 22 (19.0) | 72 (23.8) | 0.285 | |
| G-endoscopy | 63 (15.1) | 22 (19.0) | 41 (13.6) | 0.168 | |
| Invasive device | Urinary catheter | 380 (90.9) | 103 (88.8) | 277 (91.7) | 0.351 |
| Central catheter | 352 (84.2) | 93 (80.2) | 259 (85.8) | 0.161 | |
| Gastrointestinal tube | 336 (80.4) | 88 (75.9) | 248 (82.1) | 0.149 | |
| Arterial catheter | 322 (77.0) | 77 (66.4) | 245 (81.1) | 0.001 | |
| Mechanical ventilator | 275 (65.8) | 58 (50.0) | 217 (71.9) | <0.001 | |
| Drainage tube | 138 (33.0) | 42 (36.2) | 96 (31.8) | 0.390 | |
| Antibiotics | Penicillin | 274 (65.6) | 68 (58.6) | 206 (68.2) | 0.065 |
| Quinolone | 237 (56.7) | 59 (50.9) | 178 (58.9) | 0.136 | |
| Carbapenem | 228 (54.5) | 58 (50.0) | 170 (56.3) | 0.247 | |
| Cephalosporin | 225 (53.8) | 62 (53.4) | 163 (54.0) | 0.923 | |
| Vancomycin | 165 (39.5) | 43 (37.1) | 122 (40.4) | 0.533 | |
| Medication | Antiacids | 375 (89.7) | 103 (88.8) | 272 (90.1) | 0.701 |
| Steroids | 187 (44.7) | 46 (39.7) | 141 (46.7) | 0.195 | |
| TPN | 369 (88.3) | 90 (77.6) | 279 (92.4) | <0.001 |
Data are presented as n (%).
CRE, carbapenem-resistant Enterobacteriaceae; CRAB, carbapenem-resistant Acinetobacter baumannii; TPN, total parenteral nutrition.
Comparison of general characteristics between patients with healthcare-acquired and community-acquired infections
| Variables | Category | Total ( | HA ( | CA ( |
|
|---|---|---|---|---|---|
| Sex | Male | 335 (63.4) | 315 (63.4) | 20 (64.5) | 0.899 |
| Female | 193 (36.6) | 182 (36.6) | 11 (35.5) | ||
| Age (y) | 67.7±14.0 | 67.5±14.0 | 71.2±14.0 | 0.146 | |
| History of hospitalization within 6 months | No | 147 (27.8) | 136 (27.4) | 11 (35.5) | 0.310 |
| ACH | 301 (57.0) | 283 (56.9) | 18 (58.1) | ||
| LTCF | 80 (15.2) | 78 (15.7) | 2 (6.5) | ||
| Source of hospitalization | ACH, transfer | 184 (34.8) | 184 (37.0) | 0 (0) | <0.001 |
| LTCF, transfer | 76 (14.4) | 76 (15.3) | 0 (0) | ||
| Community | 268 (50.8) | 237 (47.7) | 31 (100.0) | ||
| Comorbidities[ | Hypertension | 264 (50.0) | 242 (48.7) | 22 (71.0) | 0.016 |
| Diabetes mellitus | 186 (35.2) | 171 (34.4) | 15 (48.4) | 0.114 | |
| CVD | 158 (29.9) | 155 (31.2) | 3 (9.7) | 0.011 | |
| Cancer | 140 (26.5) | 132 (26.6) | 8 (25.8) | 0.927 | |
| CKD | 64 (12.1) | 61 (12.3) | 3 (9.7) | 1.000[ | |
| Liver disease | 52 (9.8) | 49 (9.9) | 3 (9.7) | 1.000[ | |
| CRD | 49 (9.3) | 45 (9.1) | 4 (12.9) | 0.517[ | |
| Charlson comorbidity index score | 4.6±2.3 | 4.4±2.1 | 4.7±2.4 | 0.541 | |
| Treatment in ICU | No | 190 (36.0) | 159 (32.0) | 31 (100.0) | <0.001 |
| Yes | 338 (64.0) | 338 (68.0) | 0 (0) | ||
| MDRO history[ | VRE | 116 (22.0) | 113 (22.7) | 3 (9.7) | 0.088 |
| MRSA | 55 (10.4) | 53 (10.7) | 2 (6.5) | 0.760[ | |
| ESBL | 88 (16.7) | 77 (15.5) | 11 (35.5) | 0.004 | |
| MRPA | 11 (2.1) | 9 (1.8) | 2 (6.5) | 0.132[ | |
| Specimen source of CRE/CRAB | Respiratory | 317 (60.0) | 307 (61.8) | 10 (32.3) | 0.001[ |
| Rectal swab | 126 (23.9) | 117 (23.5) | 9 (29.0) | ||
| Urine | 33 (6.3) | 27 (5.4) | 6 (19.4) | ||
| Blood | 18 (3.4) | 15 (3.0) | 3 (9.7) | ||
| Others | 34 (6.4) | 31 (6.2) | 3 (9.7) | ||
| Strain of CRE/CRAB[ |
| 357 (67.6) | 345 (69.4) | 12 (38.7) | <0.001 |
| 126 (23.9) | 113 (22.7) | 13 (41.9) | 0.015 | ||
|
| 36 (6.8) | 31 (6.2) | 5 (16.1) | 0.051[ | |
| 11 (2.1) | 10 (2.0) | 1 (3.2) | 0.489[ | ||
| Others | 3 (0.6) | 2 (0.4) | 1 (3.2) | 0.166[ | |
| Status at discharge | Alive | 356 (67.4) | 335 (67.4) | 21 (67.7) | 0.969 |
| Dead | 172 (32.6) | 162 (32.6) | 10 (32.3) | ||
Data are presented as n (%) or mean±standard deviation.
HA, healthcare-acquired; CA, community-acquired; ACH, acute care hospital; LTCF, long-term care facilities; CVD, cardiovascular disease; CKD, chronic kidney disease; CRD, chronic respiratory disease; ICU, intensive care unit; MDRO, multidrug-resistant organism; VRE, vancomycin-resistant Enterococcus; MRSA, methicillin-resistant Staphylococcus aureus; ESBL, extended-spectrum β-lactamase; MRPA, multidrug-resistant Pseudomonas aeruginosa; CRE, carbapenem-resistant Enterobacteriaceae; CRAB, carbapenem-resistant Acinetobacter baumannii.
Multiple responses
Fisher exact test.
Factors associated with healthcare-acquired CRE and CRAB isolation (n=528)
| Variable | OR | 95% CI |
|
|---|---|---|---|
| Hypertension[ | 0.35 | 0.15−0.83 | 0.016 |
| Cardiovascular disease[ | 6.30 | 1.82−21.85 | 0.004 |
CRE, carbapenem-resistant Enterobacteriaceae; CRAB, carbapenem-resistant Acinetobacter baumannii; OR, odds ratio; CI, confidence interval.
Reference group=No (CRE/CRAB-isolated patients without the corresponding conditions).